Review the Use of Antivirus for COVID-19 Treatment
| Autor: | Julien Rosye Mawuntu, Herna, Lukman Prayitno, Tri Juni Angkasawati |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
2019-20 coronavirus outbreak Coronavirus disease 2019 (COVID-19) business.industry viruses Health Policy Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Public health 05 social sciences virus diseases medicine.disease 03 medical and health sciences 0302 clinical medicine 0502 economics and business Medicine 050211 marketing 030212 general & internal medicine Medical emergency business |
| Zdroj: | Journal of Health Management. 22:578-592 |
| ISSN: | 0973-0729 0972-0634 |
| Popis: | On 31 January 2020, World announced COVID-19 as an Emergency Public Health of International Concern. The number of patients in Indonesia continues to grow. Anti-viral in the COVID-19 Drug Information Laboratory in Indonesia are Lopinavir/Ritonavir, Favipiravir, Remdemsivir, Oseltamivir, Chloroquine Phosphate and Hydroxychloroquine Phosphate. Therefore, it is necessary to know the basis and management of its use. An online systematic search was performed on articles published until 30 March 2020. We use search keywords that are tailored to the purpose of writing. All six antivirals were used for the treatment of RNA virus. Chloroquine, Hydroxychloroquine and Remdesivir effectively control the SARS-CoV2 virus invitro. Lopinavir/Ritonavir, Hydroxychloroquine and Oseltamivir have been used clinically for the treatment of SARS-CoV2 virus. In 2020, there are 42 clinical trials of six antivirals. Guidance of the antivirus are from China, Belgium and Indonesia. Its differences are based on the patient’s condition. There is a lack of evidence of six antiviral effectiveness against the SARS-CoV2 virus. It has been used for other RNA viruses. It is supported by a safety profile. In a pandemic situation and the absence of a specific antivirus, the use of the six antiviruses can be done and be useful. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|